Thrombotic thrombocytopenic purpura

News and Video Search Results

News coverage

Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Business Wire 26 Mar 2024

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE: 4502/NYSE:TAK) today announced that the Japanese Ministry of Health,..

Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset
Accesswire 31 Jan 2024
FDA Approves First Treatment for Patients with Rare Inherited Blood Clotting Disorder
Upworthy 10 Nov 2023
Back To Back FDA Approval For Takeda Within Two Days, Secures Green Signal For Rare Blood Disorder Therapy
Upworthy 10 Nov 2023
Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Business Wire 09 Nov 2023

0 shares 1 views

You might like

Thrombotic thrombocytopenic purpura media coverage

FDA Grants Orphan Drug Designation to GC Biopharma's Drug Candidate for Thrombotic Thrombocytopenic Purpura

PR Newswire Asia 06 Oct 2023

YONGIN, South Korea, Oct. 6, 2023 /PRNewswire/ -- GC Biopharma Corp. announced today that GC1126A, its drug candidate for..

Technical Advancement in Apheresis Technologies to Fuel the Global Therapeutic Plasma Exchange Market - Forecast 2023-2030
GlobeNewswire 23 Aug 2023
Pivotal Phase 3 Data Presented at ISTH 2023 Congress Spotlight TAK-755 Prophylaxis for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Business Wire 25 Jun 2023
U.S. Food & Drug Administration Grants Priority Review of TAK-755 for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Business Wire 17 May 2023
Extracorporeal Shock Wave Lithotripsy Market Size to Surpass US$ 592 million by 2030 - Growth Plus Reports
GlobeNewswire 15 Mar 2023

Advertisement

More coverage

Takeda Announces Favorable Phase 3 Safety and Efficacy Results of TAK-755 as Compared to Standard of Care in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda Announces Favorable Phase 3 Safety and Efficacy Results of TAK-755 as Compared to Standard of Care in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Business Wire 05 Jan 2023

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the totality of evidence from a..

Bench-top Dental Autoclaves Market to hit US$ 13.66 billion by 2030 | Exclusive Report by Growth Plus Reports
GlobeNewswire 27 Feb 2023
Thrombocytopenia Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 27+ Companies Working in the Domain
GlobeNewswire 30 Jan 2023
Bleeding Disorder Treatment Market Size is expected to reach at USD 26,177 Million by 2030
GlobeNewswire 16 Jan 2023
Purpura Treatment Market Size, Share, Trends, Industry Growth, Key Drivers, Opportunities, Demand, Revenue and Competitive Outlook by 2029
GlobeNewswire 18 Nov 2022